This brand name is authorized in United States
The drug REGRANEX contains one active pharmaceutical ingredient (API):
|
1
Becaplermin
UNII 1B56C968OA - BECAPLERMIN
|
|
Becaplermin a recombinant human platelet-derived growth factor (rhPDGF-BB) for topical administration. Becaplermin has biological activity similar to that of endogenous platelet-derived growth factor, which includes promoting the chemotactic recruitment and proliferation of cells involved in wound repair and enhancing the formation of granulation tissue. |
This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:
| ATC code | Group title | Classification |
|---|---|---|
| D03AX06 | Becaplermin | D Dermatologicals → D03 Preparations for treatment of wounds and ulcers → D03A Cicatrizants → D03AX Other cicatrizants |
This drug has been assigned below unique identifiers within the countries it is being marketed:
| Country | Identification scheme | Identifier(s) |
|---|---|---|
| Country: US | FDA, National Drug Code | Identifier(s): 50484-810 |
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.
